The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma
Abstract
Approximately 360 million people worldwide are chronically infected with hepatitis B virus (HBV) and are at high risk of developing hepatocellular carcinoma (HCC). Chronic HBV infection is the most prevalent cause of this tumour, accounting for 55% of global cases, and 89% of those in endemic regions for HBV infection. Relative risks for developing HCC in the presence of chronic HBV infection may be as high as 49 in case-control studies, and 98 in cohort studies. HCC is the sixth most common cancer in the world today, with approximately 630,000 new cases occurring each year. It ranks third in annual cancer mortality rates. Approximately 80% of HCCs occur in developing countries where HBV infection is endemic, with the highest incidences being in the Asia-Pacific region, and sub-Saharan Africa. In the chronic carriers of the virus who are at greatest risk of developing HCC, the infection is acquired at birth or in the early months or years of life, either perinatally or horizontally, and frequently becomes chronic. The risks are greater in males, and older individuals, and are increased by co-exposure to aflatoxin B(1), the presence of cirrhosis, obesity, or diabetes mellitus, and possibly co-infection with hepatitis C virus. Viral factors that influence the risk of HCC are high viral load, the presence of certain mutations, and genotypes. Although the incidence of chronic HBV infection is beginning to decrease as a result of the universal infant immunization programme, HBV-induced HCC incidence is projected to increase for at least another two decades.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With 93 million hepatitis B carriers, perinatally acquired hepatitis B is the leading cause of adult liver cirrhosis in China [42,56,57].”
From Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis (2014) · cites this paper as [56]
In the citing paper
“With 93 million hepatitis B carriers, perinatally acquired hepatitis B is the leading cause of adult liver cirrhosis in China [42,56,57].”
From Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis (2014) · cites this paper as [56]
Citations
Cites
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Cancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Llovet, J. M., Burroughs, A. K., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,637
Lavanchy, D. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00487.x · Cited by 2,649
Primary liver cancer: Worldwide incidence and trends
Bosch, F. X., Ribes, J., Díaz, M., & Clèries, R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.011 · Cited by 2,473
Hepatitis B Virus Infection — Natural History and Clinical Consequences
Ganem, D., & Prince, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031087 · Cited by 2,361
Viral Hepatitis and Liver Disease
Vyas, G. N., Dienstag, J. L., & Hoofnagle, J. H. (1985) · Medical Entomology and Zoology · Cited by 1,867
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Yang, H., Lu, S., Liaw, Y., You, S., Sun, C., Wang, L., Hsiao, C. K., Chen, P., Chen, D., & Chen, C. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013215 · Cited by 1,220
Hepatitis B Virus Infection: Epidemiology and Vaccination
Shepard, C. W. (2006) · Epidemiologic Reviews · doi:10.1093/epirev/mxj009 · Cited by 1,152
Flagged first, then by citations
1 of the 63 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Robinson, 2005, The New Zealand hepatitis B screening programme: screening coverage and prevalence of hepatitis B infection, N Z Med J, 118, U1345
- Chia, 1996, Singapore cancer registry report No. 4. Trends in cancer incidence in Singapore 1968–1992, Singapore Cancer Rep, 4, 86
- 1994, Hepatitis viruses, vol. 59, 66
- Kew, 1998, Hepatitis C virus and hepatocellular carcinoma in developing and developed countries, Vir Hepatit Rev, 4, 259
Cited by
Sorted by citations
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
Mokdad, A. A., Lopez, A. D., Shahraz, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., & Naghavi, M. (2014) · BMC Medicine · doi:10.1186/s12916-014-0145-y · Cited by 1,129
The diagnosis and treatment of hepatocellular carcinoma
Hartke, J. G., Johnson, M. S., & Ghabril, M. (2016) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2016.12.011 · Cited by 675
Hepatitis B: Epidemiology and prevention in developing countries
Franco, E. (2012) · World Journal of Hepatology · doi:10.4254/wjh.v4.i3.74 · Cited by 577
Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region
Zhu, R., Seto, W., Lai, C., & Yuen, M. (2016) · Gut and Liver · doi:10.5009/gnl15257 · Cited by 503
Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States
Altekruse, S. F., Henley, S. J., Cucinelli, J. E., & McGlynn, K. A. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.11 · Cited by 429
Metadata
- Authors
- Kew, M. C.
- Affiliations
- University of Cape Town (ZA)
- Corresponding author
- Kew, M.C.
- Venue
- Pathologie Biologie
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 58
- Issue
- 4
- Pages
- 273-277
- ISSN
- 0369-8114 (ISSN-L)
- OpenAlex
- W1995958786
- Cited by
- 275
- References
- 63
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 16 · 2020: 13 · 2019: 26 · 2018: 12 · 2017: 21 · 2016: 22 · 2015: 28 · 2014: 36 · 2013: 27 · 2012: 25
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pathologie Biologie (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- chronic hepatitis B, hepatocellular carcinoma, HBV genotypes, HBV mutations, aflatoxin B1, liver cirrhosis, hepatitis C coinfection, cancer incidence and mortality, risk factors, developing countries
- MeSH terms
- Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Risk, Sex Factors, Aflatoxin B1, Hepatitis B Vaccines, Endemic Diseases, Hepatitis B, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review